Loading...
01/11 16:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights several positive factors: increased revenue growth guidance, improved adjusted gross margins, and strong performance in the Vascular Intervention business. The Q&A session further supports this with positive insights on market share growth and successful integration of acquisitions. Although cash flow from operations decreased, the overall financial outlook and strategic plans, including a focus on maximizing shareholder value through a potential sale, suggest a positive sentiment. The upward revision of guidance and strong market performance indicate a likely positive stock price movement in the short term.
Third Quarter Revenues $913 million, an increase of 19.4% year-over-year on a GAAP basis. Adjusted revenues were $892.9 million, up 16.8% year-over-year on a reported basis and up 15.3% on an adjusted constant currency basis. The increase was driven by operational excellence and the acquired Vascular Interventions business.
Adjusted Earnings Per Share $3.67, a 5.2% increase year-over-year. The increase was due to higher revenue, adjusted operating income, a lower tax rate, and share count, partially offset by higher interest expense and foreign exchange impacts.
Americas Revenues $555.9 million, a 7.5% increase year-over-year. Growth was driven by the acquired Vascular Intervention business and strength in Surgical, Interventional, and Vascular businesses, partially offset by OEM declines and challenges in UroLift.
EMEA Revenues $214.1 million, a 34.4% increase year-over-year. Growth was driven by the Vascular Intervention acquisition and strength in Surgical, Vascular, and Interventional businesses, partially offset by anesthesia business declines and decreased military orders.
Asia Revenues $122.9 million, a 25.3% increase year-over-year. Growth was driven by the Vascular Intervention acquisition and a $9 million stocking order for intra-aortic balloon pump and catheter growth strategy in China, partially offset by volume-based procurement.
Vascular Access Revenue $191 million, a 4.3% increase year-over-year. Growth was driven by the broad Vascular Access portfolio, including peripheral access, EZ-IO, and central access products.
Interventional Revenue $266.4 million, a 76.4% increase year-over-year. Excluding the Vascular Intervention acquisition, revenues increased 9% year-over-year. Growth was led by intra-aortic balloon pump catheters, OnControl, and complex catheters.
Anesthesia Revenue $101.4 million, a 1.4% decrease year-over-year. Decline was due to decreased military orders and softness in tracheostomy tubes, partially offset by growth in ET tubes, LMA single-use masks, and hemostatic products in the U.S.
Surgical Revenue $122.9 million, an 8.8% increase year-over-year. Growth was led by chest drainage and instrumentation, partially offset by volume-based procurement in China.
Interventional Urology Revenue $71.8 million, a 14.1% decrease year-over-year. Decline was due to pressure on UroLift, partially offset by strong double-digit growth for Barrigel.
OEM Revenue $80.4 million, a 3.9% decrease year-over-year. Decline was driven by customer inventory management, though there was a sequential revenue increase compared to the previous quarter.
Other Revenue $59 million, a 3.1% increase year-over-year. Growth was broad-based across the portfolio.
Adjusted Gross Margin 57.3%, a 350 basis point decrease year-over-year. Decline was due to tariffs, foreign exchange rates, product mix, and increased logistics and distribution costs.
Adjusted Operating Margin 23.3%, a 400 basis point decrease year-over-year. Decline was due to gross margin pressure, higher operating expenses from the Vascular Intervention acquisition, and foreign exchange impacts.
Adjusted Net Interest Expense $29.7 million, compared to $18.8 million in the prior year period. Increase was due to borrowings for the Vascular Intervention acquisition.
Adjusted Tax Rate 9.1%, compared to 13.6% in the prior year period. Decrease was due to beneficial tax provisions from the One Big Beautiful Bill Act and other nonrecurring discrete impacts.
Cash Flow from Operations (9 months) $189 million, compared to $435.6 million in the prior year period. Decrease was due to unfavorable changes in working capital, payments for tariffs, separation-related costs, and foreign tax payments.
Cash and Cash Equivalents $381.3 million at the end of the third quarter, compared to $327.7 million at year-end 2024.
Freesolve resorbable magnesium scaffold: BIOMAG-II trial reached midpoint ahead of schedule with over 1,000 patients enrolled. Data readout expected in 2027.
Barrigel: Launched in Japan during Q3 2025, targeting prostate cancer treatment. First cases performed in August, with training programs for adoption.
Geographic revenue growth: Americas revenue increased 7.5%, EMEA revenue grew 34.4%, and Asia revenue rose 25.3% year-over-year, driven by Vascular Intervention acquisition and other product strengths.
Barrigel expansion: Launched in Japan, marking a significant milestone in global expansion.
Restructuring activities: Planned workforce reductions and relocation of manufacturing operations to lower-cost locations, expected to complete by 2028.
Operational efficiencies: Focus on cost controls and tariff mitigation strategies, reducing estimated tariff impact for 2025.
Separation of Teleflex: Progress on separating into RemainCo and NewCo, with a potential sale of NewCo prioritized to maximize shareholder value.
Vascular Intervention business: Integration activities on track, achieving 6.9% year-over-year revenue growth in Q3 2025.
Separation of Teleflex into two companies: The separation process into RemainCo and NewCo could lead to operational disruptions, challenges in strategic execution, and potential inefficiencies during the transition period. Additionally, the sale of NewCo, while generating proceeds, may introduce uncertainties in market positioning and operational focus for both entities.
Italian payback measure: The Italian payback measure, which requires manufacturers to pay back excess costs to the government, poses financial risks. Although recent legislative changes reduced the amount owed, this regulation could still impact future revenue and financial stability in the region.
Intra-aortic balloon pump revenue decline: Lower-than-expected order rates for intra-aortic balloon pumps, particularly in the U.S., have led to a $30 million reduction in revenue expectations for 2025. This decline could impact overall financial performance and market share.
Foreign exchange rates: Negative impacts of foreign exchange rates have contributed to decreased gross and operating margins, posing a challenge to maintaining profitability.
Tariffs and logistics costs: Tariffs and increased logistics and distribution costs have negatively impacted gross margins, adding financial pressure to the company.
UroLift performance: Continued challenges in the UroLift business, with a 14.1% revenue decline, indicate ongoing market or operational issues that could hinder growth in the Interventional Urology segment.
Military orders and anesthesia business: Decreased military orders and softness in tracheostomy tubes have negatively impacted the anesthesia business, contributing to a 1.4% revenue decline in this segment.
Customer inventory management in OEM: OEM revenue decreased by 3.9% due to customer inventory management, reflecting potential demand fluctuations and operational inefficiencies.
Restructuring and workforce reductions: Planned restructuring activities, including workforce reductions and relocation of manufacturing operations, may lead to short-term operational disruptions and employee morale issues.
Separation of Teleflex into Two Companies: Teleflex is advancing the separation into two independent companies, RemainCo and NewCo. The process prioritizes a potential sale of NewCo, with healthy interest reported. The separation aims to create focused strategic directions, simplified operations, and tailored capital allocation strategies for each entity.
Intra-aortic Balloon Pump Revenue: Revenue expectations for intra-aortic balloon pumps have been reduced by $30 million at the midpoint of 2025 guidance due to lower-than-expected order rates, particularly in the U.S. This trend is expected to continue through Q4 2025.
2025 Adjusted Revenue Growth: Adjusted revenue growth for 2025 is now expected to be in the range of 8% to 8.5%, revised from the prior guidance of 8.5% to 9.5%. This reflects updated expectations for Q4 2025 and includes the acquired Vascular Intervention business.
Foreign Exchange Impact: A positive foreign exchange impact of $32 million is expected for 2025, representing a 100 basis point tailwind to GAAP revenue growth.
Adjusted Gross Margin and Operating Margin: For 2025, adjusted gross margin is expected to be approximately 59%, and adjusted operating margin is projected to be approximately 24.5%.
Adjusted Earnings Per Share (EPS): The adjusted EPS guidance for 2025 has been narrowed to $14 to $14.20, reflecting updated revenue and margin expectations.
Vascular Intervention Business Performance: The Vascular Intervention business achieved 6.9% year-over-year reported revenue growth in Q3 2025, modestly exceeding guidance. The business is expected to generate $204 million in revenue for the second half of 2025.
Barrigel Launch in Japan: Barrigel was launched in Japan in Q3 2025, targeting the prostate cancer market. The product aims to enhance treatment precision and reduce radiation exposure for patients undergoing therapy.
Tariff Mitigation Strategies: Tariff impact for 2025 has been revised to $25-$26 million, an improvement from the previous estimate of $29 million.
Shareholder Value Maximization: The company is committed to maximizing shareholder value through the separation of Teleflex into two independent companies, RemainCo and NewCo. This includes a potential sale of NewCo.
Capital Allocation Strategy: Proceeds from the potential sale of NewCo will be used to balance debt paydown and return capital to shareholders.
The earnings call highlights several positive factors: increased revenue growth guidance, improved adjusted gross margins, and strong performance in the Vascular Intervention business. The Q&A session further supports this with positive insights on market share growth and successful integration of acquisitions. Although cash flow from operations decreased, the overall financial outlook and strategic plans, including a focus on maximizing shareholder value through a potential sale, suggest a positive sentiment. The upward revision of guidance and strong market performance indicate a likely positive stock price movement in the short term.
The earnings call reveals several negative indicators: declining unit and dollar volumes, reduced market share, and underperformance of past loan vintages. Although there is some positive news with the 2025 vintage exceeding expectations and share repurchases, the overall sentiment is dampened by intense competition, tariffs, and rising costs. The Q&A section highlights concerns about unclear management responses and potential negative economic returns, further contributing to a negative outlook.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
